Nuveen
CLDX icon

Nuveen’s Celldex Therapeutics CLDX Stock Holding History

Nuveen’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$21.2M Buy
568,460
+366,511
+181% +$11.8M 0.01% 1230
2026
Q1 		$6.41M Buy
201,949
+1,253
+0.6% +$34.2K ﹤0.01% 1786
2025
Q4 		$5.45M Sell
200,696
-48,499
-19% -$1.28M ﹤0.01% 1876
2025
Q3 		$6.45M Sell
249,195
-16,360
-6% -$379K ﹤0.01% 1785
2025
Q2 		$5.4M Sell
265,555
-163,571
-38% -$3.18M ﹤0.01% 1838
2025
Q1 		$7.79M Buy
429,126
+140,748
+49% +$3.14M ﹤0.01% 1696
2024
Q4 		$7.29M Sell
288,378
-75,257
-21% -$2.04M ﹤0.01% 1778
2024
Q3 		$12.4M Sell
363,635
-68,245
-16% -$2.6M ﹤0.01% 1479
2024
Q2 		$16M Buy
431,880
+62,797
+17% +$2.37M ﹤0.01% 1281
2024
Q1 		$15.5M Buy
369,083
+247,888
+205% +$10.2M ﹤0.01% 1328
2023
Q4 		$4.81M Buy
121,195
+915
+0.8% +$26.9K ﹤0.01% 2003
2023
Q3 		$3.31M Sell
120,280
-688
-0.6% -$21.6K ﹤0.01% 2068
2023
Q2 		$4.1M Buy
120,968
+420
+0.3% +$14.2K ﹤0.01% 2019
2023
Q1 		$4.34M Sell
120,548
-9,862
-8% -$426K ﹤0.01% 1973
2022
Q4 		$5.81M Sell
130,410
-19,236
-13% -$687K ﹤0.01% 1826
2022
Q3 		$4.21M Sell
149,646
-4,324
-3% -$133K ﹤0.01% 2002
2022
Q2 		$4.15M Buy
153,970
+20,044
+15% +$582K ﹤0.01% 2065
2022
Q1 		$4.55M Sell
133,926
-3,433
-2% -$110K ﹤0.01% 2111
2021
Q4 		$4.99M Sell
137,359
-10,129
-7% -$441K ﹤0.01% 2114
2021
Q3 		$8.02M Buy
147,488
+5,457
+4% +$256K ﹤0.01% 1931
2021
Q2 		$4.75M Buy
+142,031
New +$3.9M ﹤0.01% 2275
2015
Q2 		– Sell
-506
Closed -$211K – 1605
2015
Q1 		$211K Buy
+506
New +$181K ﹤0.01% 1507
2014
Q2 		– Sell
-5,763
Closed -$1.53M – 1607
2014
Q1 		$1.53M Sell
5,763
-234
-4% -$89.6K 0.01% 927
2013
Q4 		$2.18M Buy
5,997
+419
+8% +$161K 0.01% 754
2013
Q3 		$2.96M Buy
+5,578
New +$1.91M 0.02% 653

Other funds holding CLDX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Nuveen's CLDX Position: Q2 2026 in Review

Nuveen increased its Celldex Therapeutics (CLDX) stake by 181% in Q2 2026, buying an estimated $11.8M and bringing the position to 568,460 shares worth $21.2M. The position accounts for 0.01% of the portfolio, ranked #1230.

Nuveen first reported a position in CLDX in Q3 2013 and has held it in 25 quarters since. 254 funds tracked by Wall St. Rank hold CLDX as of Q2 2026.

  • Nuveen held 568,460 shares of Celldex Therapeutics worth $21.2M as of Q2 2026.
  • Nuveen bought 366,511 Celldex Therapeutics shares in Q2 2026, an estimated $11.8M.
  • Celldex Therapeutics made up 0.01% of Nuveen's portfolio in Q2 2026, its #1230 holding.
  • Nuveen first reported a position in Celldex Therapeutics in Q3 2013 and has held it in 25 quarters since.
  • 254 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q2 2026.

Based on Nuveen's 13F filing for Q2 2026, filed 11 Aug 2026.